Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

HA14-1

Copy Product Info
😃Good
Catalog No. T1980Cas No. 65673-63-4

HA14-1, a Bcl-2/Bcl-XL antagonist, is a non-peptidic ligand of a Bcl-2 surface pocket (IC50: ~9 μM).

HA14-1

HA14-1

Copy Product Info
😃Good
Purity: 98%
Catalog No. T1980Cas No. 65673-63-4
HA14-1, a Bcl-2/Bcl-XL antagonist, is a non-peptidic ligand of a Bcl-2 surface pocket (IC50: ~9 μM).
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
10 mg$39In StockIn Stock
25 mg$62In StockIn Stock
50 mg$89In StockIn Stock
100 mg$128-In Stock
1 mL x 10 mM (in DMSO)$30In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98%
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
HA14-1, a Bcl-2/Bcl-XL antagonist, is a non-peptidic ligand of a Bcl-2 surface pocket (IC50: ~9 μM).
Targets&IC50
Bcl-2:9 μM
In vitro
In immunodeficient mice, HA14-1 (400 nM) does not significantly affect the growth of glioblastomas on its own. However, in vivo, HA14-1 (400 nM) enhances the efficacy of the DNA-damaging agent etoposide (2.5 mg/kg) in inhibiting the growth of glioblastomas.
In vivo
When applied to follicular lymphoma cell lines HF1A3, HF4.9, and HF28RA, HA14-1 exhibits cytotoxicity with LC50 values of 4.5/12.6/8.1 μM, respectively. HA14-1 induces apoptosis in HL-60 cells in a dose-dependent manner through the activation of caspases. Moreover, HA14-1 triggers apoptosis in HF4.9, HF1A3, and HF28RA cells through caspase and ROS (Reactive Oxygen Species) pathways.
Kinase Assay
Affinity determination: The binding affinity of organic compounds to Bcl-2 protein in vitro is determined by a competitive binding assay based on fluorescence polarization. For this assay, 5-carboxyfluorecein is coupled to the N terminus of a peptide, GQVGRQLAIIGDDINR, derived from the BH3 domain of Bak (Flu-BakBH3), which has been shown to bind to the surface pocket of the Bcl-xL protein with high-affinity. According to our molecular modeling studies and binding measurement using fluorescence polarization, the Flu-BakBH3 peptide binds the surface pocket of Bcl-2 with a similar affinity. Bcl-2 used in this assay is a recombinant GST-fused soluble protein. Flu-BakBH3 and Bcl-2 protein are mixed in the presence or absence of organic compounds under standard buffer conditions and are incubated for 30 min. The binding of Flu-BakBH3 to Bcl-2 protein is measured on a LS-50 luminescence spectrometer equipped with polarizers using a dual path length quartz cell (500 μl). The fluorophore is excited with vertical polarized light at 480 nm (excitation slit width 15 nm), and the polarization value of the emitted light is observed through vertical and horizontal polarizers at 530 nm (emission slit width 15 nm). The binding affinity of each compound for Bcl-2 protein is assessed by determining the ability of different concentrations of the compound to inhibit Flu-BakBH3 binding to Bcl-2.
Cell Research
The cytotoxic effects of HA14-1 against different FL cell lines are determined by the MTT assay. Briefly, the cells (5000/well) are incubated in triplicate in 96-well plate in the presence or absence of HA14-1 for 20 h at 37 °C. Thereafter, the MTT solution is added to each well. After 4 h incubation at 37 °C, the optical density (OD) is measured by means of 96-well plate reader, with the extraction buffer as a blank. The following formula is used: percentage cell viability = (OD of the experiment samples/OD of the control) × 100. Sigmoidal dose-response curves are fitted to the mean cell viability plotted against log HA14-1 dose and lethal concentration 50% (LC50) values are calculated from the resulting curves using Prism 4.0 softw(Only for Reference)
Chemical Properties
Molecular Weight409.23
FormulaC17H17BrN2O5
Cas No.65673-63-4
SmilesCCOC(=O)C(C#N)C1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12
Relative Density.1.48g/cm3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
Ethanol: 40.9 mg/mL (99.94 mM), Sonication is recommended.
DMSO: 40.9 mg/mL (99.94 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.89 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
Ethanol/DMSO
1mg5mg10mg50mg
1 mM2.4436 mL12.2181 mL24.4361 mL122.1807 mL
5 mM0.4887 mL2.4436 mL4.8872 mL24.4361 mL
10 mM0.2444 mL1.2218 mL2.4436 mL12.2181 mL
20 mM0.1222 mL0.6109 mL1.2218 mL6.1090 mL
50 mM0.0489 mL0.2444 mL0.4887 mL2.4436 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy HA14-1 | purchase HA14-1 | HA14-1 cost | order HA14-1 | HA14-1 chemical structure | HA14-1 in vivo | HA14-1 in vitro | HA14-1 formula | HA14-1 molecular weight